Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
Atreca, Inc. (BCEL)
Last atreca, inc. earnings: 3/11 04:30 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform Phase 1b clinical trial in patients with solid tumors to begin in early 2020 REDWOOD CITY, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020. “The FDA’s clearance of our IND application for ATRC-101 is a significant milestone for Atreca and validates the ability of our differentiated drug discovery platform to generate novel clinical candidates against cancer,” said John Orwin, Chief Executiv
Show less
Read more
Impact Snapshot
Event Time:
BCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCEL alerts
High impacting Atreca, Inc. news events
Weekly update
A roundup of the hottest topics
BCEL
News
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCXPR Newswire
- Immunome: An Oncology Powerhouse In The Making [Seeking Alpha]Seeking Alpha
- Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors [Yahoo! Finance]Yahoo! Finance
BCEL
Earnings
- 11/14/23 - Miss
BCEL
Sec Filings
- 4/22/24 - Form DEFM14A
- 4/17/24 - Form 4
- 4/11/24 - Form PREM14A
- BCEL's page on the SEC website